PD57-04 EXPLORATION OF SERUM BIOMARKERS TO PREDICT AXITINIB EFFICACY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) III1 Apr 2018PD57-04 EXPLORATION OF SERUM BIOMARKERS TO PREDICT AXITINIB EFFICACY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Naoko Honma, Norihiko Tsuchiya, Takamitsu Inoue, Taketoshi Nara, Sohei Kanda, Kazuyuki Numakura, Hiroshi Tsuruta, Mitsuru Saito, Shintaro Narita, Shigeru Satoh, and Tomonori Habuchi Naoko HonmaNaoko Honma More articles by this author , Norihiko TsuchiyaNorihiko Tsuchiya More articles by this author , Takamitsu InoueTakamitsu Inoue More articles by this author , Taketoshi NaraTaketoshi Nara More articles by this author , Sohei KandaSohei Kanda More articles by this author , Kazuyuki NumakuraKazuyuki Numakura More articles by this author , Hiroshi TsurutaHiroshi Tsuruta More articles by this author , Mitsuru SaitoMitsuru Saito More articles by this author , Shintaro NaritaShintaro Narita More articles by this author , Shigeru SatohShigeru Satoh More articles by this author , and Tomonori HabuchiTomonori Habuchi More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2648AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES With multiple molecular-targeted agents available, an optimal therapeutic strategy for treating individual patients with metastatic renal cell carcinoma (mRCC) is urgently required. Predicting drug efficacy may contribute to the development of personalized medicine. We analyzed serum levels of various biomarkers before and after axitinib treatment to predict its efficacy in patients with mRCC. METHODS We collected serum samples from 44 patients with mRCC who were treated with axitinib between September 2012 and October 2015. The patients were orally administered 10 mg axitinib twice daily until disease progression or intolerance. Serum levels of biomarkers were measured with the magnetic bead array using the Bio-Plex ProTM Human Cancer Biomarker Panels before and 4 weeks after initiating axitinib treatment. The panels contain 34 molecules such as sEGFR, FGF-basic, follistatin, G-CSF, HGF, sHER-2/neu, sIL-6Rα, leptin, osteopontin, PECAM- 1, PDGF-AB/BB, prolactin, SCF, sTIE-2, sVEGFR-1, sVEGFR-2, angiopoietin-2, sCD40L, EGF, endoglin, sFASL, HB-EGF, IGFBP-1, IL-6, IL-8, IL-18, PAI-1, PLGF, TGF-α, TNF-α, uPA, VEGF-A, VEGF-C, and VEGF-D, which are related to angiogenesis or cell proliferation. The associations between the serum levels of the molecules and clinical outcomes after axitinib treatment, including progression-free survival (PFS) and overall survival (OS), were statistically analyzed. RESULTS The median PFS and OS were 10.7 and 35.0 months, respectively. The best clinical response was a partial response in 16 patients (38.1%), stable disease in 20 (45.5%), and progressive disease in six (13.6%). Patients with decreased serum PAI-1 levels from baseline at 4 weeks after axitinib treatment had significantly better PFS and OS than those without (15.0 vs. 5.1 months; p = 0.027 and 35.0 vs. 14.2 months; p = 0.026). Multivariate analyses revealed that decreased serum PAI-1 level was an independent predictor of PFS and OS (p = 0.015 and p = 0.032). CONCLUSIONS Initial changes in serum PAI-1 levels are potentially useful as predictive biomarkers of clinical efficacy in patients with mRCC who were treated with axitinib. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e1068 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Naoko Honma More articles by this author Norihiko Tsuchiya More articles by this author Takamitsu Inoue More articles by this author Taketoshi Nara More articles by this author Sohei Kanda More articles by this author Kazuyuki Numakura More articles by this author Hiroshi Tsuruta More articles by this author Mitsuru Saito More articles by this author Shintaro Narita More articles by this author Shigeru Satoh More articles by this author Tomonori Habuchi More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...